Floatz logo

Carboplatin

Prostate Neuroendocrine Neoplasm

Phanes TherapeuticsSmall moleculePhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

31 Active assets in the Prostate Neuroendocrine Neoplasm cohort.

Asset / SponsorPhaseRating
Tarlatamab
Inkeun Park
Phase 2B
Oxodotreotide
Novartis Pharmaceuticals
Phase 2B
Alisertib
Weill Medical College of Cornell University
Phase 2B
Tislelizumab
Translational Research in Oncology
Phase 2CCC
Sacituzumab Tirumotecan
Virginia Commonwealth University
Phase 2CCC

View all 34 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaActive
A
Indicative · Phase 4
80 / 100
View asset →
primary peritoneal carcinomaActive
BBB
Indicative · Phase 3
76 / 100
View asset →
non-small cell squamous lung carcinomaActive
BBB
Indicative · Phase 3
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →